Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 1.00 |
| ▸ | VCP | P55072 | 2/20 | 0.72 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.72 |
| ▸ | MBD2 | Q9UBB5 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 5/20 | 0.65 |
| ▸ | NPC1 | O15118 | 5/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | MAPT | P10636 | 5/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.63 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.63 |
| ▸ | AGER | Q15109 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL486534 | 0.90 | ALOX5 (0.82) | ALOX5VCPAMY1AMBD2MEN1 | |
| SCHEMBL7114964 | 0.88 | ALOX5 (1.00) | ALOX5VCPAMY1AMBD2MEN1 | |
| SCHEMBL1822611 | 0.85 | SMN1; SMN2 (0.84) | ALOX5VCPAMY1AMEN1NPC1 | |
| SCHEMBL7115473 | 0.84 | ALOX5 (0.73) | ALOX5VCPAMY1AMBD2MEN1 | |
| SCHEMBL1822783 | 0.84 | ALOX5 (1.00) | ALOX5VCPAMY1AMEN1NPC1 | |
| SCHEMBL23742626 | 0.83 | CYP1A1 (0.88) | ALOX5VCPAMY1AMEN1NPC1 | |
| SCHEMBL6798095 | 0.83 | ALOX5 (0.71) | ALOX5VCPAMY1AMEN1NPC1 | |
| SCHEMBL13224426 | 0.82 | ALOX5 (0.70) | ALOX5VCPAMY1AMBD2MEN1 | |
| SCHEMBL29737068 | 0.82 | CSNK2A1 (0.80) | ALOX5MEN1NPC1KMT2AMAPT | |
| SCHEMBL28482021 | 0.82 | CSNK2A1 (0.80) | ALOX5MEN1NPC1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066758-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF CANCERS, INCLUDING HEPATOCELLULAR CARCINOMA, AND AS INHIBITORS OF HEPATITIS VIRUS REPLICATION | INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH | 2017-03-09 | — | — | US | claimed |
| US-20140249154-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF CANCERS, INCLUDING HEPATOCELLULAR CARCINOMA, AND AS INHIBITORS OF HEPATITIS VIRUS REPLICATION | BARUCH S. BLUMBERG INSTITUTE | 2014-09-04 | — | — | US | claimed |
| CN-103957908-A | Substituted aminothiazoles as inhibitors of cancer including hepatocellular carcinoma and as inhibitors of hepatitis virus replication | INST HEPATITIS & VIRUS RES | 2014-07-30 | — | — | CN | claimed |
| WO-2008101029-A2 | USE OF THIAZOLE, OXAZOLE AND IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-08-21 | — | — | WO | claimed |
| US-20170066758-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF CANCERS, INCLUDING HEPATOCELLULAR CARCINOMA, AND AS INHIBITORS OF HEPATITIS VIRUS REPLICATION | INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH | 2017-03-09 | — | — | US | disclosed |
| US-20170066758-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF CANCERS, INCLUDING HEPATOCELLULAR CARCINOMA, AND AS INHIBITORS OF HEPATITIS VIRUS REPLICATION | INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH | 2017-03-09 | — | — | US | disclosed |
| US-20140249154-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF CANCERS, INCLUDING HEPATOCELLULAR CARCINOMA, AND AS INHIBITORS OF HEPATITIS VIRUS REPLICATION | BARUCH S. BLUMBERG INSTITUTE | 2014-09-04 | — | — | US | disclosed |
| US-20140249154-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF CANCERS, INCLUDING HEPATOCELLULAR CARCINOMA, AND AS INHIBITORS OF HEPATITIS VIRUS REPLICATION | BARUCH S. BLUMBERG INSTITUTE | 2014-09-04 | — | — | US | disclosed |
| WO-2008101029-A2 | USE OF THIAZOLE, OXAZOLE AND IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249154-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF CANCERS, INCLUDING HEPATOCELLULAR CARCINOMA, AND AS INHIBITORS OF HEPATITIS VIRUS REPLICATION | HCCS, BCAT1, AADAT | ALOX5 2655/4885VCP 2673/4885AMY1A 4524/4885 |
| US-20170066758-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF CANCERS, INCLUDING HEPATOCELLULAR CARCINOMA, AND AS INHIBITORS OF HEPATITIS VIRUS REPLICATION | HDGF, HCCS, BCAT1 | ALOX5 3197/4885VCP 2801/4885AMY1A 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.